Skip to main content

Table 2 Anticoagulation effect of rivaroxaban in 24 patients, measured in PPP using different clotting assays

From: Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs

 

Peak of activity* in hours

Trough of activity** in hours

 

(mean ± SD, 2.06 ± 0.29)

(mean ± SD, 23.4 ± 1.09)

Ratio

R-PT

R-aPTT

R-TT

R-VV

R-C

R-PT

R-aPTT

R-TT

R-VV

R-C

Mean

1.72

1.32

1.15

3.08

3.53

1.20

1.08

1.11

1.66

1.89

SD

0.39

0.16

0.16

0.88

0.68

0.12

0.13

0.11

0.37

0.42

Median

1.61

1.28

1.11

2.75

3.53

1.17

1.03

1.2

1.62

1.97

Highest

2.53

1.74

1.67

5.13

5.63

1.46

1.38

1.26

2.35

2.88

Lowest

1.08

1.1

1.0

1.92

2.24

1.04

0.95

0.9

0.86

0.98

  1. *p < 0.01 for R-VV vs. R-PT, R-aPTT, and R-TT; p < 0.01 for R-C vs. R-PT, R-aPTT, and R-TT.
  2. **p < 0.05 for R-C vs. R-PT, R-aPTT, and RTT; p < 0.05 for R-VV vs. R-PT, R-aPTT, and RTT.
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us